Development of protective anti-Mycoplasma pneumoniae antibodies after immunization of guinea pigs with the combination of a P1-P30 chimeric recombinant protein and chitosan.
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“They further designed a chimeric protein combining these regions, which induced monospecific antiserum that significantly reduced M. pneumoniae adherence to human bronchial epithelial cells (Schurwanz et al., 2009; Hausner et al., 2013).”
From Advances in adhesion-related pathogenesis in Mycoplasma pneumoniae infection (2025) · cites this paper as Hausner et al., 2013
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mycoplasma pneumoniae and Its Role as a Human Pathogen
Waites, K. B., & Talkington, D. F. (2004) · Clinical Microbiology Reviews · doi:10.1128/cmr.17.4.697-728.2004 · Cited by 1,339 · cited 1×
“Thus, live attenuated vaccines did not reach the stage of clinical trials [1] and there is a need for a new vaccination strategy based on the growing knowledge of specific pathogen-host interactions.”
BackgroundProteome organization in a genome-reduced bacterium
Kühner, S., van Noort, V., Betts, M. J., Leo-Macias, A., Batisse, C., Rode, M., Yamada, T., Maier, T., Bader, S., Beltran-Alvarez, P., et al. (2009) · Science · doi:10.1126/science.1176343 · Cited by 471
Interaction of Mycoplasmas With Host Cells
Rottem, S. (2003) · Physiological Reviews · doi:10.1152/physrev.00030.2002 · Cited by 432
Research works printed but not linked: 42
- Atkinson, 2008, Epidemiology, clinical manifestations, pathogenesis and laboratory detection of Mycoplasma pneumoniae infections, FEMS Microbiol Rev, 32, 956, 10.1111/j.1574-6976.2008.00129.x · DOI · Paper page
- von Baum, 2009, Mycoplasma pneumoniae pneumonia revisited within the German competence network for community-acquired pneumonia (CAPNETZ), BMC Infect Dis, 9, 62, 10.1186/1471-2334-9-62 · DOI
- Tsiodras, 2005, Central nervous system manifestations of Mycoplasma pneumoniae infections, J Infect, 51, 343
- Zhao, 2013, Surveillance of macrolide-resistant Mycoplasma pneumoniae in Beijing, China, from 2008 to 2012, Antimicrob Agents Chemother, 57, 1521, 10.1128/AAC.02060-12 · DOI
- Linchevski, 2009, Mycoplasma pneumonia vaccine protection efficiency and adverse reactions – systematic review and meta-analysis, Vaccine, 27, 2437, 10.1016/j.vaccine.2009.01.135 · DOI
- Dandekar, 2000, Re-annotating the Mycoplasma pneumoniae genome sequence: adding value, function and reading frames, Nucleic Acids Res, 28, 3278, 10.1093/nar/28.17.3278 · DOI · Paper page
- Hames, 2009, Glycerol metabolism is important for cytotoxicity of Mycoplasma pneumoniae, J Bacteriol, 191, 747, 10.1128/JB.01103-08 · DOI · Paper page
- Schmidl, 2011, A trigger enzyme in Mycoplasma pneumoniae: impact of the glycerophosphodiesterase GlpQ on virulence and gene expression, PLoS Pathog, 7, e1002263, 10.1371/journal.ppat.1002263 · DOI · Paper page
- Kannan, 2006, ADP-ribosylating and vacuolating cytotoxin of Mycoplasma pneumoniae represents unique virulence determinant among bacterial pathogens, Proc Natl Acad Sci U S A, 103, 6724, 10.1073/pnas.0510644103 · DOI · Paper page
- Krause, 2004, Cellular engineering in a minimal microbe: structure and assembly of the terminal organelle of Mycoplasma pneumoniae, Mol Microbiol, 51, 917, 10.1046/j.1365-2958.2003.03899.x · DOI
- Balish, 2006, Mycoplasmas: a distinct cytoskeleton for wall-less bacteria, J Mol Microbiol Biotechnol, 11, 244, 10.1159/000094058 · DOI
- Schurwanz, 2009, A strategy to create chimeric proteins derived from functional adhesin regions of Mycoplasma pneumoniae for vaccine development, Infect Immun, 77, 5007, 10.1128/IAI.00268-09 · DOI · Paper page
- Romero-Arroyo, 1999, Mycoplasma pneumoniae protein P30 is required for cytadherence and associated with proper cell development, J Bacteriol, 181, 1079, 10.1128/JB.181.4.1079-1087.1999 · DOI
- Lamm, 1997, Interaction of antigens and antibodies at mucosal surfaces, Ann Rev Microbiol, 51, 311, 10.1146/annurev.micro.51.1.311 · DOI · Paper page
- Arca, 2009, Chitosan-based systems for the delivery of vaccine antigens, Expert Rev Vaccines, 8, 937, 10.1586/erv.09.47 · DOI · Paper page
- Pavot, 2012, New insights in mucosal vaccine development, Vaccine, 30, 142, 10.1016/j.vaccine.2011.11.003 · DOI · Paper page
- Dumke, 2008, Characterisation of subtype and variant-specific antigen regions of the P1 adhesin of Mycoplasma pneumoniae, Int J Med Microbiol, 298, 483, 10.1016/j.ijmm.2007.06.002 · DOI
- Dumke, 2007, Sensitive detection of Mycoplasma pneumoniae in human respiratory tract samples by optimized real-time PCR approach, J Clin Microbiol, 45, 2726, 10.1128/JCM.00321-07 · DOI
- Berger, 2004, Structure and interactions in chitosan hydrogels by complexation or aggregation for biomedical application, Eur J Pharm Biopharm, 57, 35, 10.1016/S0939-6411(03)00160-7 · DOI · Paper page
- Korsmeyer, 1982, Mechanism of solute release from porous hydrophilic polymers, Int J Pharm, 15, 25, 10.1016/0378-5173(83)90064-9 · DOI · Paper page
- Waring, 2001, Development of a genomics-based PCR assay for detection of Mycoplasma pneumoniae in a large outbreak in New York State, J Clin Microbiol, 39, 1385, 10.1128/JCM.39.4.1385-1390.2001 · DOI
- Klement, 2006, Identification of risk factors for infection in an outbreak of Mycoplasma pneumoniae respiratory tract disease, Clin Infect Dis, 43, 1239, 10.1086/508458 · DOI
- Walter, 2008, Community outbreak of Mycoplasma pneumoniae infection: school-based cluster of neurologic disease associated with household transmission of respiratory illness, J Infect Dis, 198, 1365, 10.1086/592281 · DOI
- Sliman, 2009, Outbreak of acute respiratory disease caused by Mycoplasma pneumoniae on board a deployed U.S. navy ship, J Clin Microbiol, 47, 4121, 10.1128/JCM.01926-09 · doi:10.1128/jcm.01926-09
- Pereyre, 2012, Clonal spread of Mycoplasma pneumoniae in primary school, Bordeaux, France, Emerg Infect Dis, 18, 343, 10.3201/eid1802.111379 · DOI
- Barile, 1988, Immunization against Mycoplasma pneumoniae disease: a review, Isr J Med Sci, 20, 912
- Barile, 1988, Hamster challenge potency assay for evaluation of Mycoplasma pneumoniae vaccines, Infect Immun, 56, 2450, 10.1128/IAI.56.9.2450-2457.1988 · DOI
- Couch, 1964, Infection with artificially propagated Eaton agent (Mycoplasma pneumoniae). Implications for development of attenuated vaccine for cold agglutinin-positive pneumonia, J Am Med Assoc, 187, 442, 10.1001/jama.1964.03060190058015 · DOI
- Smith, 1967, Inactivated Mycoplasma pneumoniae vaccine. Evaluation in volunteers, J Am Med Assoc, 199, 353, 10.1001/jama.1967.03120060051007 · doi:10.1001/jama.1967.03120060051007
- Su, 1990, Sequence divergency of the cytadhesin gene of Mycoplasma pneumoniae, Infect Immun, 58, 2669, 10.1128/IAI.58.8.2669-2674.1990 · DOI
- Layh-Schmitt, 1997, The adhesin related 30-kDa protein of Mycoplasma pneumoniae exhibits size and antigen variability, FEMS Microbiol Lett, 152, 101, 10.1111/j.1574-6968.1997.tb10415.x · doi:10.1111/j.1574-6968.1997.tb10415.x
- Brandtzaeg, 2003, Role of secretory antibodies in the defence against infections, Int J Med Microbiol, 293, 3, 10.1078/1438-4221-00241 · DOI · Paper page
- Oliveira, 2007, Intranasal vaccines for protection against respiratory and systemic bacterial infections, Expert Rev Vaccines, 6, 419, 10.1586/14760584.6.3.419 · doi:10.1586/14760584.6.3.419
- Lee, 2000, Bioadhesive-based dosage forms: the next generation, J Pharm Sci, 89, 850, 10.1002/1520-6017(200007)89:7<850::AID-JPS2>3.0.CO;2-G · DOI · Paper page
- Illum, 2001, Chitosan as a novel nasal delivery system for vaccines, Adv Drug Deliv Rev, 51, 81, 10.1016/S0169-409X(01)00171-5 · DOI · Paper page
- Ralli-Jain, 2010, Enhancement of the protective efficacy of a Chlamydia trachomatis recombinant vaccine by combining systemic and mucosal routes for immunization, Vaccine, 28, 7659, 10.1016/j.vaccine.2010.09.040 · doi:10.1016/j.vaccine.2010.09.040
- Crouch, 2005, The use of a systemic prime/mucosal boost strategy with an equine influenza ISCOM vaccine to induce protective immunity in horses, Vet Immunol Immunopathol, 108, 345, 10.1016/j.vetimm.2005.06.009 · doi:10.1016/j.vetimm.2005.06.009
- McCluskie, 2002, Parenteral and mucosal prime-boost immunization strategies in mice with hepatitis B surface antigen and CpG DNA, FEMS Immunol Med Microbiol, 32, 179, 10.1111/j.1574-695X.2002.tb00551.x · doi:10.1111/j.1574-695x.2002.tb00551.x
- Davenport, 2000, A homing selection hypothesis for T-cell trafficking, Immunol Today, 21, 315, 10.1016/S0167-5699(00)01644-3 · doi:10.1016/s0167-5699(00)01644-3
- Bellanti, 2004, Immunologic studies of specific mucosal and systemic immune responses in Mexican school children after booster aerosol or subcutaneous immunization with measles vaccine, Vaccine, 22, 1214, 10.1016/j.vaccine.2003.09.032 · doi:10.1016/j.vaccine.2003.09.032
- Baumann, 2008, Mucosal vaccination against bacterial respiratory infections, Expert Rev Vaccines, 7, 1257, 10.1586/14760584.7.8.1257 · DOI
- Baudner, 2005, Protective immune responses to meningococcal C conjugate vaccine after intranasal immunization of mice with the LTK63 mutant plus chitosan or trimethyl chitosan chloride as novel delivery platform, J Drug Target, 13, 489, 10.1080/10611860500353195 · doi:10.1080/10611860500353195
Cited by
Advances in adhesion-related pathogenesis in Mycoplasma pneumoniae infection
Sun, B., Ling, Y., Li, J., Ma, L., Jie, Z., Luo, H., Li, Y., Yin, G., Wang, M., Meng, F., et al. (2025) · Frontiers in Microbiology · doi:10.3389/fmicb.2025.1613760 · Cited by 18
Metadata
- Authors
- Hausner, M., Schamberger, A., Naumann, W., Jacobs, E., & Dumke, R.
- Venue
- Microbial Pathogenesis
- Publisher
- Elsevier BV
- Published
- 2013-11
- Volume
- 64
- Pages
- 23-32
- ISSN
- 0882-4010
- Cited by
- 29
- References
- 3
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.